GLP1R and type 2 diabetes mellitus: Thanks to the intrinsic low risk of hypoglycaemia associated with GLP-1 RA of SGLT2i, these drugs allow to safely achieve the recommended HbA1c levels, even in patients with advanced diabetes, thus allowing more aggressive treatment of T2DM.